- Home
- MPA vs STRO Comparison
MPA vs STRO Comparison
Compare MPA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPA
- STRO
- Stock Information
- Founded
- MPA 1992
- STRO 2003
- Country
- MPA United States
- STRO United States
- Employees
- MPA N/A
- STRO N/A
- Industry
- MPA Finance Companies
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPA Finance
- STRO Health Care
- Exchange
- MPA Nasdaq
- STRO Nasdaq
- Market Cap
- MPA 150.5M
- STRO 147.6M
- IPO Year
- MPA N/A
- STRO 2018
- Fundamental
- Price
- MPA $11.39
- STRO $1.27
- Analyst Decision
- MPA
- STRO Strong Buy
- Analyst Count
- MPA 0
- STRO 7
- Target Price
- MPA N/A
- STRO $12.14
- AVG Volume (30 Days)
- MPA 25.2K
- STRO 870.7K
- Earning Date
- MPA 01-01-0001
- STRO 03-24-2025
- Dividend Yield
- MPA 3.83%
- STRO N/A
- EPS Growth
- MPA N/A
- STRO N/A
- EPS
- MPA N/A
- STRO N/A
- Revenue
- MPA N/A
- STRO $160,955,000.00
- Revenue This Year
- MPA N/A
- STRO N/A
- Revenue Next Year
- MPA N/A
- STRO N/A
- P/E Ratio
- MPA N/A
- STRO N/A
- Revenue Growth
- MPA N/A
- STRO 230.90
- 52 Week Low
- MPA $9.87
- STRO $1.26
- 52 Week High
- MPA $12.21
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- MPA 39.41
- STRO 34.83
- Support Level
- MPA $11.58
- STRO $1.26
- Resistance Level
- MPA $11.82
- STRO $1.59
- Average True Range (ATR)
- MPA 0.09
- STRO 0.13
- MACD
- MPA -0.01
- STRO -0.02
- Stochastic Oscillator
- MPA 0.00
- STRO 12.90
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.